Top Markets
#1 Akedo Akedo +60.74%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +49.99%
#4 Velvet Velvet +41.65%
#5 Black Phoenix Black Phoenix +34.54%
#6 Ο„emplar Ο„emplar +27.45%
#7 Ribbita by Virtuals Ribbita by Virtuals +18.82%
#8 Bitway Bitway +17.84%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +15.42%
#10 Cap Cap +15.27%
Coin of the day
Akedo Akedo
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
CohBar, Inc. CohBar, Inc.

CohBar, Inc.

CWBR
Peringkat dalam Saham #38304
CohBar Inc. is a clinical-stage biotechnology company dedicated to the... CohBar Inc. is a clinical-stage biotechnology company dedicated to the discovery and advancement of therapies that leverage mitochondrial biology, known as mitochondria-based therapeutics (MBTs). Their primary objective is to combat chronic conditions and diseases associated with aging. These MBTs are being developed to address a broad spectrum of medical challenges, including non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis (IPF), type 2 diabetes, acute respiratory distress syndrome (ARDS), various cancers, and cardiovascular disorders like Alzheimer's disease. Their flagship clinical asset is CB4211, an innovative, optimized analogue of the MOTS-c mitochondrial-derived peptide. This candidate is currently undergoing Phase Ib evaluation as part of a larger Phase Ia/Ib clinical trial, specifically targeting non-alcoholic steatohepatitis (NASH) and obesity. Beyond their clinical work, CohBar's preclinical portfolio features CB5138 analogs aimed at fibrotic conditions, as well as CB5064 analogs being explored for their potential in treating ARDS linked to COVID-19. Established in 2007, CohBar, Inc. maintains its corporate headquarters in Menlo Park, California.
Harga Saham
$0.41
Terakhir disinkronkan: 2025-01-23
Kapitalisasi Pasar
$1.08M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan CohBar, Inc. (CWBR)

Kategori

Healthcare
Pendapatan untuk CohBar, Inc. (CWBR)
Pendapatan pada Jun 2023 TTM: 0.00
Menurut laporan keuangan terbaru dari CohBar, Inc., pendapatan saat ini (TTM) adalah 0.00. Pada tahun 2021, perusahaan menghasilkan pendapatan sebesar 0.00 sama dengan pendapatan pada tahun 2020 yang sebesar 0.00. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan CohBar, Inc. dari 2012 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Mengubah
2026 (TTM) 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
Pendapatan untuk perusahaan serupa atau pesaing
Perusahaan Pendapatan Perbedaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE